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Abstract
Background: Existing observational studies provide conflicting evidence for the causal
effect of metformin use on cancer risk in patients with type-2 diabetes, and there are con-
cerns about bias affecting a number of studies.
Methods: MEDLINE was used to identify observational studies investigating the associ-
ation between metformin and overall or site-specific cancer in people with type-2
diabetes. A systematic data extraction and bias assessment was conducted, in which risk
of eight bias domains (outcome, exposure, control selection, baseline confounding,
time-dependent confounding, immortal time, missing data, censoring methods) were as-
sessed against pre-defined criteria, and rated as unlikely, low, medium or high.
Results: Of 46 studies identified, 21 assessed the effect of metformin on all cancer.
Reported relative risks ranged from 0.23 to 1.36, with 10/21 reporting a statistically sig-
nificant protective effect and two a harmful effect. The range of estimates was similar for
site-specific cancers; 3/46 studies were rated as low or unlikely risk of bias in all domains.
Two of these had results consistent with no effect of metformin; one observed a moder-
ate protective effect overall, but presented further analyses that the authors concluded
were inconsistent with causality. However, 28/46 studies were at risk from bias through
exposure definition, 22 through insufficient baseline adjustment and 35 from possible
time-dependent confounding.
Conclusions: Observational studies on metformin and cancer varied in design, and the
majority were at risk of a range of biases. The studies least likely to be affected by bias
did not support a causal effect of metformin on cancer risk.
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Introduction
Research exists to suggest type 2 diabetes mellitus (T2DM)
may be a risk factor for cancer,1,2 and observational stud-
ies have suggested that diabetic therapies could also affect
this risk.3–5 Multiple observational studies have reported
an apparent protective effect of metformin, a common
first-line therapy for T2DM, against incidence of any can-
cer.5–9 However, a number of potential biases have been
identified within some of these studies.10 There are limited
data from clinical trials comparing metformin with other
treatments, though one meta-analysis of adverse events
from trials did not find any association between metformin
use and cancer occurrence.11.
Particular difficulties arise for observational studies in
this context because treatment with metformin for T2DM
changes through time (is ‘time varying’), and is influenced
by disease severity. This means that disease severity may be
a confounder between metformin use and cancer, but will
also be on the causal pathway since metformin is pre-
scribed in order to control disease severity. For example,
glycated haemoglobin (HbA1c), a measure of long-term
blood glucose control, and body mass index (BMI) are pre-
dictive of metformin use according to well-defined treat-
ment guidelines for T2DM,12 but use of metformin will
likely influence future HbA1c and BMI. There is also evi-
dence that both BMI13 and HbA1c14 affect cancer risk. In
this situation, standard statistical models cannot estimate
the true causal effect of time-varying treatment.15
Throughout this paper, such time-updated variables that
may be both confounders of, and on the causal pathway
for the association between exposure and outcome are
referred to as ‘time dependent confounders affected by
prior treatment’ (Box 1).
Reviews to date have examined existing evidence for the
link between metformin use and cancer; however, some
were not comprehensive10 and others have not systematically
evaluated or presented a detailed evaluation of bias.16–21
The aim of this study was to summarize existing obser-
vational studies investigating possible associations between
metformin use and cancer risk in patients with T2DM, and
to systematically examine the research design and analysis
methods with regard to risk of bias. A secondary aim was
to use meta-regression to estimate the extent to which these
biases may account for the differences between study
estimates.
Methods
Search strategy
MEDLINE was searched by R.F. using OvidSP on 30 May
2014 for all English-language published articles on cancer
Key Messages
• Many existing observational studies investigating the effect of metformin use on cancer incidence in patients with
type 2 diabetes have risk of bias.
• No studies to date have used appropriate statistical models to estimate the effect of time-varying treatment correctly
controlling for time-dependent confounders which may be affected by previous treatment.
• Studies at lowest risk of bias do not support the hypothesis that metformin is protective against cancer.
• Previously reported large protective associations are unlikely to be causal.
BOX 1. Key definition: ‘time-dependent confounder
affected by previous treatment
A variable is a time-dependent confounder if it satis-
fies the following conditions:
i. the variable changes through time;
ii. values are predictive of treatment initiation;
iii. the variable is also associated with the outcome
of interest.
When the time-dependent confounder is also affected
by previous treatment, as depicted in the causal dia-
gram below, standard statistical methods cannot pro-
vide unbiased estimates of the total causal effect of
time-varying treatment.
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risk and type 2 diabetes treatments from 1946 onwards.
The search involved using MeSH headings as well as key-
word searches in the title and abstract. The full search
terms are presented in Supplementary data (available at
IJE online). Conference abstracts and unpublished studies
were excluded.
Screening strategy
Articles were included in the review if they were of a stand-
ard epidemiological design and presented original observa-
tional research. Reviews and meta-analysis were not
included. Studies were required to present a measure of ef-
fect of metformin on risk of cancer incidence (either all
cancer or site-specific) in patients with T2DM, with age
adjustment as a minimum. Studies restricted to populations
with additional comorbidities or diseases were excluded.
During an initial title and abstract screen, reviews, meta
analyses and editorial pieces that looked at metformin and
cancer were retained so that reference lists could be
checked. Additionally, papers that appeared not to meet
inclusion criteria, for example those that had primarily
compared cancer incidence between diabetics and non-
diabetics, were kept for full-text screening in case the
required measure of effect was reported as a secondary
analysis. A full-text screening was then applied to the re-
maining papers, and the reference lists of relevant reviews
and meta analyses searched. A 10% random sample of the
extracted studies were screened by an additional researcher
(H.F.) to test the reliability of the inclusion criteria. A
Cohens kappa score22 was calculated to give a quantitative
measure of rater reliability, with a value of 0.75 used as
the threshold for ‘excellent agreement’.23.
Data extraction and bias assessment
The data extraction table was piloted on five studies (by
R.F., K.B. and D.F.) and subsequently refined to ensure
systematic documentation of the relevant information. An
example extraction table is supplied in Supplementary
Table 1 (available as Supplementary data at IJE online).
Although none of the investigators were blinded to the
aims of the review, detailed criteria for assessment of bias
were produced in order to consider risks of bias for each
study. The eight domains assessed for bias were: (i) out-
come definition; (ii) exposure definition (including choice
of comparator): (iii) control selection (case control studies
only); (iv) consideration of HbA1c, BMI and other antidia-
betic drugs as time-dependent confounders affected by pre-
vious treatment (Box 1); (v) adjustment for baseline (study
entry) confounders (smoking, diabetes severity, age, gen-
der); (vi) immortal time (cohort studies only); (vii) missing
data; and (viii) censoring methods (cohort studies only).
For each bias domain, pre-defined criteria allowed catego-
rization into high, medium, low or unlikely risk of bias.
Bias in study estimate occurs when aspects of the design or
data analysis either induce or fail to eliminate non-causal
imbalances in risk of cancer between those who are
exposed or unexposed. How this may occur is dependent
on the bias domain in question, and detailed criteria for
each domain are presented in Supplementary Table 2
(available as Supplementary data at IJE online). Broadly,
studies were considered at unlikely risk of bias in a particu-
lar domain if the design and analysis methods were un-
likely to induce a systematic difference between risk of
cancer between metformin users and non-users. Low risk
meant that there was small possibility of bias but the po-
tential magnitude of the bias was unlikely to materially af-
fect the overall study conclusions. Medium and high risk
of bias meant that there was potential for some or substan-
tial effect of bias on the study estimate, respectively.
Although the specific criteria for each bias domain may
have left some room for subjectivity, they were developed
and agreed in advance by R.F., K.B. and D.F. to make
them as objective as possible.
Time-dependent confounders affected by previous treat-
ment were considered as a separate domain in addition to
baseline confounding, to highlight the difference between
baseline confounding that could be easily adjusted for in a
standard analysis, and the more subtle bias that may arise
if time-dependent confounders affected by previous treat-
ment are not correctly adjusted for. If studies omitted a
particular confounder because they found it did not alter
the estimate of metformin on cancer risk in a multivariable
model, then they were not deemed to be at risk of bias due
to its exclusion. However, the timing and accuracy of the
confounder were still considered as sources of bias, since
these aspects could have resulted in its incorrect omission.
Bias from outcome and exposure definition encom-
passed both misclassification bias, biases induced by tim-
ing of measurement, and whether the definitions may
introduce selection bias. Potential bias induced by using
time-varying exposure without consideration for the time
needed for exposure to plausibly cause cancer, could be
considered as inappropriate censoring or as inappropriate
exposure definition; to avoid double counting, this was
considered a censoring bias.
Some studies provided multiple estimates based on
dose-response categories (13 studies), or differing com-
parators (five studies). In this situation, the main estimate
used for our analyses was that deemed to be most compar-
able to other studies. For multiple estimates from a dose-
response model, if an overall exposed vs non-exposed
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estimate was not presented (five studies), a middle category
best representing a moderate level of exposure was taken.
Meta-regression
As an exploratory analysis designed to investigate whether
between-study heterogeneity in the observed effect of met-
formin could be explained by bias and other study level
factors, a random effects meta-regression was performed.
Separate regressions were performed for the five most com-
mon outcomes: all cancer, colorectal/bowel cancer, lung
cancer, breast cancer and pancreatic cancer. Studies that
reported only stratum-specific results (three studies) were
each entered into a meta-analysis to generate a pooled esti-
mate for that study, which was subsequently used in the
meta-regression.
Study characteristics evaluated in the meta-regression
were a subset of all available, based on a priori assump-
tions about which might have the largest impact on study
estimates. Characteristics included were comparator ex-
posure [diet only, other oral antidiabetic drugs (OADs),
less metformin and no metformin (diet and other OADs
combined)], bias in exposure definition, bias in outcome
definition, bias from baseline adjustments, bias from time-
dependent confounders, immortal time bias and whether
the cohort were incident users of diabetic drugs. Zero was
assigned to studies rated as unlikely or low in the bias as-
sessment, and one to those rated medium or high. A binary
variable was used to reduce sparsity. Backwards stepwise
selection was used to identify which characteristics best ex-
plained study heterogeneity. A P-value cut-off of 0.4 was
used due to small sample size and the large number of par-
ameters in the full model. Analysis was conducted using
STATA v14.
Results
Search and screening
The numbers of studies included/excluded at each stage of
the process are presented in Figure 1. From an initial 822
references (779 after removal of duplicates), 46 studies
were included in the final review. Full texts were available
for all studies. The random sample of 76 studies independ-
ently screened by two researchers against the inclusion cri-
teria resulted in a Cohen’s kappa of 0.79, and only a single
initial disagreement over inclusion of a study; it was agreed
on discussion that this study did meet the inclusion criteria.
One article examined adverse event reports from two
randomized controlled trials and so was technically not ob-
servational; however, it was included as it could be con-
sidered a retrospective cohort study with a trial-based data
source. It did not adjust for age, but this exclusion criterion
was waived since treatment was randomized.
Table 1 summarizes the data sources, outcomes, expos-
ure definitions, timing of exposure measurements and com-
parator exposures used. More detailed study-level
information is presented in Supplementary Table 3 (avail-
able as Supplementary data at IJE online).
Study characteristics
Of the 46 studies, 22 were case-control design7,22–24 and
24 were cohort studies.3,5,8,9,45–63 Data from electronic
health records were used by 37 (80%) of the studies: most
commonly, the UK’s Clinical Practice Research Datalink
(CPRD) (13 studies) and the Taiwan National Health
Insurance Claims Database (eight studies). As previously
mentioned, one paper51 used data from two randomized
controlled trials. The remaining eight (all case-control) col-
lected data from a specific cancer or diabetes clinic.
A total of 22 studies (46%) defined exposure to metfor-
min as any exposure, without considering overall duration.
Three further studies refined this definition by requiring a
minimum time period or number of prescriptions before an
individual was considered exposed. Nine studies (20%)
looked at monotherapy with metformin and 10 studies
(22%) used total exposure to enable dose-response ana-
lyses. The remaining two studies looked at metformin in
combination with specific OADs, with a comparator group
that allowed the estimation of the effect of just metformin.
The most frequently used comparator group was no met-
formin, used in 24 studies (52%). Use of sulphonylurea
[another popular first-line oral agent; 11 studies (24%)]
was also a common comparator.
There were 116 estimates presented for the effect of met-
formin on risk of cancer when considering separate estimates
for different cancer sites. A total of 21 studies examined the
outcome of all cancers excluding non-melanoma skin cancer
(NMSC). Colorectal and/or bowel (14 studies) were the
most common sites studied, followed by pancreas (13 stud-
ies), breast (13 studies), lung (12 studies) and prostate (11
studies). Other sites had less than 10 estimates each.
Effect of metformin on cancer risk
Figure 2 displays the study estimates and 95% confidence
intervals (CIs) for relative risk [odds ratio (OR) or hazard
ratio (HR)] of metformin use on incidence of all cancer.
Estimates and 95% CIs for the four most commonly
studied site-specific cancers are presented in Figure 3.
For all cancer, 16/21 studies estimated a protective ef-
fect of metformin, with 10/16 having upper confidence
limits below 1. The magnitude of the effect estimates
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ranged from just a 0.04% reduction in risk45 to a 77% re-
duction in risk.49 Two studies estimated a statistically sig-
nificant harmful effect of metformin, with estimates of
1.36 (1.1 –1.54)3 and 1.10 (1.00–1.20).47 For site-specific
cancers, estimates were also highly variable across studies
(Figure 3).
Bias evaluation
Only three studies51,61,62 scored low or unlikely for risk
of bias in all categories. One further study, which looked
at lung cancer only, scored unlikely or low in all catego-
ries, except missing data43 where it was rated unknown.
Three of these studies saw no evidence of an effect of
Figure 1. Flow chart of screening process detailing number of studies excluded at each stage and reason for exclusions.
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metformin. One study estimated a modest protective ef-
fect of long-term use (> 60 months) in comparison with
short-term use (0-6 months) with a hazard ration (HR) of
0.82 (0.75-0.90), but ultimately concluded that there was
no evidence for a causal effect due to patterns of risk that
were inconsistent with causality.62
Table 1. Frequency tables to summarize data source, outcome and exposure definitions for 46 studies
Case-control N (%) Cohort N (%) Total N (%)
Data source
Clinical trial 0 (0) 1 (4) 1 (2)
Diabetes Registry 2 (9) 4 (17) 6 (13)
Insurance database 2 (9) 9 (38) 11 (24)
CPRD (or GPRD) 8 (36) 6 (25) 14 (30)
Other primary/secondary care database 1 (5) 4 (17) 5 (11)
Recruited from hospital/clinic 9 (41) 0 (0) 9 (20)
Outcome definitiona
All cancer 5 (23) 16 (67) 21 (46)
Colorectal/bowel 2 (9) 12 (50) 14 (3)
HCC/ICC 5 (23) 2 (8) 7 (15)
Ovarian/endometrial 2 (9) 1 (4) 3 (7)
Bladder 0 (0) 3 (13) 3 (7)
Breast 3 (14) 10 (42) 13 (28)
Oesophagus 0 (0) 4 (17) 4 (9)
Kidney 0 (0) 2 (8) 2 (4)
Liver 0 (0) 5 (21) 5 (11)
Leukaemia 0 (0) 1 (4.2) 1 (2)
Lung 4 (18) 8 (33) 12 (26)
Melanoma 0 (0) 2 (8) 2 (4)
Pancreas 3 (14) 10 (42) 13 (28)
Prostate 3 (14) 8 (33) 11 (24)
Stomach 1 (5) 4 (17) 5 (11)
Definition of exposure to metformin for primary estimate
Any exposure 14 (64) 8 (33) 22 (48)
Any exposure but minimum time/number of prescriptions needed 1 (5) 2 (8) 3 (7)
Total exposure (number of prescriptions/time on metformin) 6 (27) 4 (17) 10 (22)
Monotherapy 1 (5) 8 (33) 9 (20)
Randomization 0 (0) 1 (4) 1 (2)
Combination therapy with sulphonylurea 0 (0) 1 (4) 1 (2)
Timing of exposure measurement
Current use (at time of cancer/matched date) 3 (14) 0 (0) 3 (7)
Time updated (current/ever/cumulative) 0 (0) 8 (33) 8 (17)
Fixed from start of follow-up, with exposure occurring in a baseline
period or follow-up starting from first exposure ((ITT)
0 (0) 8 (33) 8 (17)
Single summary measure of exposure over entire follow-up 19 (86) 8 (33) 27 (59)
Comparator group for primary estimate
Less exposure (i.e. continuous exposure variable) 0 (0) 2 (8) 2 (4)
Diet only 0 (0) 1 (4) 1 (2)
Rosiglitazone 0 (0) 1 (4) 1 (2)
Sulphonylurea 2 (9) 9 (38) 11 (24)
Any other OAD 3 (14) 4 (17) 7 (15)
No metformin (combination of diet and other OADs) 17 (77) 7 (29) 24 (52)
bNew users of OADs
Yes 3 (14) 7 (29) 10 (22)
No 17 (77) 12 (50) 29 (63)
Unsure 2 (9) 5 (21) 7 (15)
CPRD, Clinical Practice Research Datalink; GPRD, General Practice Research Database; HCC, Heaptocellular Carcinoma; ICC Intrahepatic
Cholangiocarcinoma ; OAD, oral diabetic agent.
aStudies may have multiple outcomes; therefore column percentages will not sum to 1.
bBased on whether clear description is given in methods.
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Study-specific results of bias assessment for studies assess-
ing all cancer as an outcome are displayed alongside risk esti-
mates in Figure 2. Of the 10 studies that estimated a
statistically significant protective effect of metformin, nine
had at least medium risk of bias in at least two domains; sev-
en had medium or high risk of bias from exposure definition;
and seven had medium or high risk of bias for treatment of
HbA1c, BMI and other OADs. Bias assessments for all other
studies are presented in Supplementary Table 4 (available as
Supplementary data at IJE online).
Time-dependent confounders affected by previous
treatment (HbA1c, BMI other antidiabetics)
Only four studies were considered as unlikely to be af-
fected by bias due to how HbA1c, BMI and other antidia-
betic treatments were accounted for in the analysis. These
studies considered exposure to metformin as fixed from
baseline [‘intention to treat’ (ITT) principle], and had con-
founders measured immediately before baseline.
Only 16/47 studies included HbA1c as a confounder in
the final model. Six further studies reported considering it
as a potential confounder, but did not include it in their
final model due to lack of statistical significance3,45 or be-
cause it did not alter the results of the multivariable mod-
el.25,27,59,61 All but one of these studies61 were still
considered at risk since it was questionable whether the
HbA1c used was representative of HbA1c at the time of
starting treatment; 26 studies accounted for BMI in their
final model. In most case-control studies, the measurement
of HbA1c and BMI preceded the date of cancer diagnosis
(or matched date for the control) but it was rarely clear
where this occurred in relation to the measurement of ex-
posure, and therefore the potential for these studies to have
adjusted for factors on the causal pathway between metfor-
min and cancer was high. For the cohort studies, most used
BMI and HBA1c measurements at or close to the time of co-
hort entry, which therefore either preceded or coincided
with exposure classification. None of the studies reviewed
used time-updated values of either HbA1c or BMI, though
some used averages across follow-up.
The appropriate adjustment for other antidiabetic drugs
is dependent upon the exposure and comparator group def-
initions. In six of the cohort studies examined, adjustment
for use of other diabetic drugs was not neces-
sary.8,9,51,59,61,64 In the remaining studies, 22 accounted
for OADs. Tables 2 (case-control) and 3 (cohort) detail
which adjustments were made, and the timing of the meas-
urement within the follow-up period for each study
separately.
Other sources of bias
Exposure definition (n ¼ 28) and baseline adjustments (n
¼ 22) were the other most common reasons for medium or
high risk of bias. The exposure definition was most likely
to have introduced bias in case-control studies by having
different time windows to measure exposure, meaning the
Figure 2. Estimated relative risk (odds ratio or hazard ratio) with 95% CI for the 21 studies examining use of metformin and risk of all cancers, and cor-
responding assessment of bias according to pre-specified criteria.
a Represents the hazard ratio for cancer risk per one extra prescription of metformin.
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Figure 3. Estimated relative risk (odds ratio or hazard ratio) with 95% CI for 4 most commonly studied site specific cancers. Case control studies are
represented by hollow triangle, Cohort studies by filled circles.
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overall chance of seeing individuals exposed to metformin
is systematically different between the cases and controls.
Bias was most often introduced into cohort studies because
future information was used to inform exposure definition;
7/24 cohort studies were considered to have high risk of
immortal time bias. In all, 22 studies were considered at
risk of bias from confounding due to incomplete or in-
appropriate baseline adjustment because either the com-
parator used may have resulted in comparing patients at
differing disease stages without adjustment for baseline
disease severity, or measures of severity used in the adjust-
ment could be on the causal pathway between exposure
and outcome, therefore not correctly accounting for differ-
ences in disease severity that may have influenced choice of
treatment at baseline.
In addition, 36 studies were considered at risk of bias
due to not considering a latency period for cancer (out-
come definition). Since the effect of this bias is prob-
ably small in magnitude, this was considered to be low
risk. This was supported by the five studies that considered
different latency periods in sensitivity analyses, concluding
that estimates did not differ substantially.9,24,43,60,61
Many studies were considered as at unknown risk of
bias for censoring (12/24 cohort studies) and missing data
(16 studies) due to a lack of information. Particularly for
censoring, few cohort studies reported the numbers lost to
follow-up or for what reason. Four studies were rated me-
dium or high for risk of bias from missing data, three of
these because the missing indicator method was used,
which will increase the risk of residual confounding.65
With these three studies having > 20% missing data, the
effect of residual confounding could be large.
Meta-regression
Table 4 presents estimates and model diagnostics for the
final meta-regression models obtained. For the outcome of
all cancer, after backwards stepwise selection, the only
Table 2. Adjustment method for key time-dependent confounders affected by previous treatment: case-control studies
Study name HbA1c BMI Other diabetic medication
Adjusted
for value
before
first
exposure
Adjusted
for value
between
exposure
and
index datea
Adjusted
for value
at index
datea
Adjusted
for value
before
first
exposure
Adjusted
for value
between
exposure
and
index datea
Adjusted
for value
at index
datea
Adjusted
for value
before first
exposure
Adjusted
for value
between
exposure
and
index datea
Adjusted
for value
at index
datea
Azoulay et al. (2011)24   
Becker et al. (2013)25  
Bodmer et al. (2011)29   
Bodmer et al. (2010)30   
Bodmer et al. (2012) (Lung)26  
Bodmer et al. (2012) (Pancreatic)28  
Bodmer et al. (2012) (Colorectal)27  
Bosco et al. (2011)31
Chaiteerakij et al. (2013)32
Dabrowski et al. (2013)34 
Donadon et al. (2010)35  
Li et al. (2009)37  
Evans et al. (2005)7 
Hassan et al. (2012)38
Margel et al. (2013)39 
Mazzone et al. (2012)40  
Monami et al. (2009)42   
Monami et al. (2011)41  
Smiechowski et al. (2013)43 b  b  b 
Wang et al. (2013)44
Chen et al. (2013)33 
Donadon et al. (2010)36 
aIndex date, time of cancer diagnosis/matched date for control.
bSensitivity analysis assessed whether there was a difference between adjusting for covariates measured before exposure or any time between 1 year before ex-
posure and index date.
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study level predictor that remained in the model was the
comparator group. The model estimated that using a com-
parator group of diet, as opposed to no metformin, made
metformin appear more protective, whereas using other
OADs or less metformin as a reference group made metfor-
min appear less protective. However, this model was only
predicted to explain 7% of the between-study variance.
The comparator group was also retained in the models for
lung, breast and pancreatic cancer; however in these mod-
els, using other OADs as the comparator was estimated to
make metformin appear more protective.
The strongest predictor of heterogeneity for studies of
lung cancer was risk of bias from exposure definition which,
if present, was estimated to reduce the log risk ratio by 0.44,
95% CI (0.17, 0.72) P ¼ 0.007, making metformin appear
more protective. For breast cancer, the strongest predictor
was use of an incident user cohort, which made metformin
look less protective. This predictor was also identified for
studies of lung and pancreatic cancer, but the estimates had
much less precision. Presence of both time-dependent and
baseline confounding was also estimated to influence study
heterogeneity for breast cancer, with presence of these biases
estimated to have equal and opposite effects on the log risk
ratio. For colorectal cancer, the final model included only
immortal time bias. As expected, risk of this bias was esti-
mated to make metformin appear more protective.
Table 3. Adjustment method for key time-dependent confounders affected by previous treatment: cohort studies
Study name HbA1c BMI Other diabetic medication
Adjusted
for value
at cohort
entry (at
time of
or prior
to first
exposure)
Adjusted
as a time-
updated
variable
Measured
as an
average of
values at
any point
after
exposure
Adjusted
for value
at cohort
entry (at
time of
or prior
to first
exposure)
Adjusted
as a time-
updated
variable
Measured
as an
average
of values
at any
point after
exposure
Adjusted
for value
at cohort
entry (at
time of
or prior
to first
exposure)
Adjusted
as a time-
updated
variable
Measured
as an
average of
values at
any point
after
exposure
Currie et al. (2009)3
Currie et al. (2013)47  
Geraldine et al. (2012)49  a
dHome et al. (2010)51
Hsieh et al. (2012)8
Lai et al. (2012) (HCC)52
Lai et al. (2012) (LUNG)53
Lee et al. (2011)54 
Libby et al. (2009)5   b
eQiu et al. (2013)59
Redaniel et al. (2012)60  
eRuiter et al. (2012)9
eTsilidis et al. (2014)61 
Yang et al. (2011)63   
Buchs and Silverman (2011)45 
Oliviera et al. (2008)58
Hense et al. (2011)50  
Chiu et al. (2013)46
Ferrara et al. (2011)48  
Lehman et al. (2012)55 
Morden et al. (2011)56 c c
Neumann et al. (2011)57 
Van Staa et al. (2012)62  
eMorgan et al. (2012)64  
aWeight used instead of BMI.
bMeasured within 3 months/1 year of cohort entry (either side of first exposure).
cDiabetes complications used as proxy measures for severity.
dTreatment randomised so no adjustment necessary.
eAdjustment for use of other OADs not necessary as study looked at incident users of diabetes medications and censored at change in medication.
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Discussion
The 46 studies examined in this review did not provide
consistent evidence to support a protective effect of metfor-
min on risk of cancer. Two of three studies with low or un-
likely risk of bias for all categories had estimates consistent
with no effect of metformin. The third study had an esti-
mate consistent with a moderate protective effect; however
this study included many analyses, and also reported that
when comparing metformin exposure with other classes of
oral antidiabetics, the risk of cancer did not differ between
drugs. The authors also found that the incidence rates of
cancer were higher in the first 3 months after therapy initi-
ation, which they suggested might be due to detection bias,
which would also explain why longer exposure appears
protective when compared with the first 6 months of
therapy.
The estimates of effect reported across the 46 studies
were highly variable for all outcomes studied. Many stud-
ies were at high risk of bias from exposure definition
which, for reasons already outlined by Suissa and
Azoulay,10 can have a large effect on estimates of risk.
Within studies considered to be at low or unlikely risk of
such bias, effect estimates were closer to the null but there
was still variation in point estimates, albeit with some wide
confidence intervals. Figure 4 displays the study estimates
from Figure 2 ordered by risk of bias from exposure defin-
ition (left) to demonstrate this. It is possible that
confounding by disease severity, and in particular con-
founding from time-dependent variables affected by pre-
vious treatment, could partly explain the remaining
heterogeneity in observed estimates. By assigning values of
0, 1, 2 and 3 to unlikely, low, medium and high risk, re-
spectively, and summing over all domains, an overall bias
score was calculated. When ordered by this score [Figure 4
(right)] it is clear that heterogeneity increases as risk of bias
increases, and the strongest protective effects are from
those studies with the highest risk of bias overall.
The bias evaluation performed was detailed and thor-
ough, and every effort was made to agree in advance the
criteria for risk of bias in each of the eight domains exam-
ined. However, as in all studies of this kind, it was not pos-
sible to eliminate all subjectivity from this process.
Figure 5A represents the total causal effect of metformin
use on cancer risk that we wish to estimate in a simple ex-
ample where we assume HbA1c is the only time-dependent
confounder affected by previous treatment (as previously
defined in Box 1). Figure 5 B, C and D illustrates the causal
pathways that are actually being estimated under the three
approaches most commonly used in the studies examined in
this review. In Figure 5B, studies adjust for HbA1c but the
measurement is taken any time during follow-up, which
may result in ‘adjusting out’ any effect of metformin that is
mediated through HbA1c. In Figure 5C, because treatment
may change after baseline, the single adjustment at time 0
may lead to residual confounding by post-baseline HbA1c.
Figure 4. Estimates of relative risk of cancer from metformin use, ordered by risk of bias from exposure assessment only (left) and by overall risk of
bias (right). Overall bias score is sum of bias risk over all domains, with unlikely ¼ 0, low ¼ 1, medium ¼ 2, high ¼ 3. Case control studies are repre-
sented by hollow triangle, Cohort studies by filled circle.
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In Figure 5D, the fixing of exposure from baseline removes
the issue of time-dependent confounding and therefore
allows the total effect of exposure on cancer to be estimated,
but typically estimates an ITT effect only, which may not be
appropriate given that patients are unlikely to adhere to a
single treatment throughout follow-up. One study adjusted
for non-adherence61 using a method that produces an un-
biased estimate if there are no unmeasured confounders of
the association between non-adherence and outcome,66 but
the validity of this assumption is questionable. This ap-
proach is also limited by considering comparisons between
active drugs only. When applied and analysed carefully, it
will give an unbiased estimate of the effect of initiating met-
formin compared with initiating (as an example)
sulphonylurea on development of cancer. However, this is
not necessarily equivalent to estimating causal pharmaco-
logical effect of metformin use on cancer incidence and may
be inappropriate if the comparator in question may itself
affect risk of cancer. Most studies with low risk of other
biases used the approach outlines in 5D. The lack of vari-
ation in how time-dependent confounders were adjusted for
in these studies mean that it is not possible with the current
literature alone to assess whether there is a meaningful im-
pact of time-dependent confounders affected by previous
treatment on the estimated effect of metformin on cancer
risk.
In order to estimate the causal pharmacological effect
of metformin on risk of cancer, the ideal would be to emu-
late a randomized controlled trial where patients are
randomized to either metformin or diet only. This would
involve comparison of patients initiating metformin with
those controlling their disease by diet only, and correctly
adjusting for disease severity at time of initiation while
maintaining the effect of previous treatment on future
disease severity measures. Causal methodology has been
successfully used in other areas to overcome issues with
Figure 5. Directed Acyclic Graphs (DAGs) to represent estimated causal pathways for A) the desired total causal effect of treatment on cancer risk,
and B)-D) the estimated effect under different methods of adjustment for time dependent confounders affected by prior treatment. Box indicates ad-
justment. Dotted line represents causal associations that are present but not included in the desired/estimated effect.
A Solid lines represent the pathways needed to estimate the total causal effect of time varying treatment on cancer.
B HbA1c measured at a single time point during the measurement window (usually the most recent value). Exposure may be time updated or
assumed fixed from cohort entry. Solid line represents the pathways included in the estimate of effect under this approach.
C HbA1c measured once at/before cohort entry, exposure modelled as time varying. Solid line represents the pathways included in the estimate of ef-
fect under this approach.
D Exposure is assigned at cohort entry and assumed fixed (Intention to treat (ITT) principle), HbA1c measured once at/before cohort entry. Solid line
represents the pathways included in the estimate of effect under this approach.
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time-dependent confounders affected by previous treat-
ment,67,68 and could be applied to this question as a valu-
able addition to the current literature.
These causal inference methods (marginal structural
models with inverse probability of treatment weighting or
the g-computation formula) may be required to fully guard
against some of the potential biases we identified, notably
time-dependent confounders affected by previous treat-
ment.69 However, even with standard analytical
approaches, careful study design and analysis can minimize
the risk of bias being introduced. For example, it is desir-
able to clearly identify incident users of oral diabetes medi-
cations, ideally in patients with newly diagnosed diabetes,
and to ensure that important confounders such as HbA1c,
BMI and other disease severity measures are recorded and
adjusted for at study entry–either before or at the time of
medication initiation. This will ensure that disease severity
is broadly balanced at study entry, and that the effect of
medication on future values of important covariates is not
eliminated. In addition, if medication use is not assumed to
be fixed from baseline, then it is important to classify time
before first exposure as unexposed in order to avoid intro-
ducing immortal time bias. Secondary analyses to look at
effects of cumulative exposure, and sensitivity analysis
with exclusion of periods in which un-diagnosed cancer
may be affecting probability of treatment, would also be
advisable to establish whether observed associations are
likely to be causal.
This review has systematically identified and assessed
the existing literature on the pharmacoepidemiological
question of metformin use and cancer risk. The search
identified a large number of studies from varying countries
and journals, and the inclusion criteria were shown to have
good reliability between raters. Only one database was
used in the search, and therefore some relevant literature
may have been omitted from the review. However, by
searching reference lists of other meta-analyses and system-
atic reviews, the majority of studies will still have been
identified. Since performing the original search, it is likely
that new studies will also have been published on the topic;
however, a brief updated search did not identify any new
studies that used methods substantially different from
those covered in this review, though one study used slightly
more sophisticated methods to deal with baseline con-
founding by indication.70 The meta-regression aimed to es-
tablish whether any of the potential sources of bias could
explain the heterogeneity in risk estimates. A comparator
group was selected for the final model in four of the five
analyses as a predictor of heterogeneity, but the direction
of effect was inconsistent between models. Use of a non-
incident user cohort was also identified in three models as
a predictor of heterogeneity, but estimates of how this
would affect study results were imprecise.
The overall reliability of the meta-regression results is
questionable. For all cancer there were 21 studies contribu-
ting to this analysis, and even after selecting only key study
level predictors, there were nine parameters in the initial
model. The analysis was likely underpowered, and back-
ward selection may not have produced reliable results.
Additionally, many of these estimates lacked precision. For
the site-specific cancers, since the sample sizes for the meta-
regressions were smaller, these issues may be enhanced fur-
ther and individual studies with extreme estimates are likely
to have had a large influence. Furthermore for some biases,
two high-risk studies could be rated as such for different
reasons, which would bias the estimate in opposite direc-
tions, resulting in the bias appearing to have no effect over-
all. In addition, the ability to examine only published
studies may itself introduce a publication bias which cannot
be accounted for in a meta-regression. Also as previously
mentioned, the bias evaluation could not be perfectly object-
ive, which adds further uncertainty to any results of this
analysis. Therefore, overall the results of this exploratory
analysis should be interpreted cautiously.
Overall, the existing literature provides inconsistent an-
swers to the question of metformin use and cancer risk in
type 2 diabetes. Variation in design of studies and the po-
tential for many kinds of bias make it difficult to explain
the differences in risk estimates, particularly in terms of the
potential impact of less easily detectable bias such as that
from time-dependent confounders affected by previous
treatment. It is likely that the largest protective effects that
have been observed are a result of immortal time bias and
other issues relating to how metformin use is defined.
Studies without such biases tend to have estimates closer to
the null, and whereas an effect of metformin use on risk of
subsequent cancer in patients with type 2 diabetes cannot
be excluded, the previously reported large protective asso-
ciations are unlikely to be causal.
Supplementary Data
Supplementary data are available at IJE online.
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